| |
Patients with AS (N = 1,250)
|
|---|
| | | |
Prior TNF antagonist(s)
|
Reason for discontinuation of prior TNF antagonista
|
|---|
| |
No prior ETN/IFX
|
Prior ETN and/or IFX
|
IFX only
|
ETN only
|
IFX and ETN
|
Lack of response
|
Loss of response
|
Intolerance
|
|---|
|
Characteristic
|
(n = 924)
|
(n = 326)
|
(n = 162)
|
(n = 85)
|
(n = 79)
|
(n = 64)
|
(n = 115)
|
(n = 56)
|
|---|
|
Male (%)
|
71
|
72
|
78
|
59
|
72
|
75
|
66
|
68
|
|
Age (years; mean ± SD)
|
44 ± 12
|
44 ± 11
|
44 ± 10
|
44 ± 12
|
43 ± 10
|
45 ± 10
|
42 ± 10
|
44 ± 13
|
|
AS duration (years; mean ± SD)
|
11 ± 10
|
11 ± 9
|
12 ± 9
|
9 ± 9
|
11 ± 8
|
10 ± 9
|
11 ± 8
|
12 ± 10
|
|
HLA-B27 positive (%)
|
83
|
81
|
80
|
82
|
81
|
86
|
82
|
84
|
|
Peripheral arthritis (%)b
|
22
|
25
|
26
|
27
|
19
|
23
|
24
|
34
|
|
Enthesitis (%)c
|
55
|
55
|
52
|
57
|
60
|
50
|
56
|
64
|
|
Concomitant NSAIDs (%)
|
77
|
66
|
69
|
57
|
71
|
53
|
68
|
66
|
|
C-reactive protein (mg/dl)d
|
1.3
|
1.2
|
1.4
|
1.1
|
1.1
|
1.4
|
1.6
|
0.8
|
| |
0.6, 2.6
|
0.5, 2.6
|
0.5, 3.0
|
0.4, 2.2
|
0.4, 2.6
|
0.7, 2.8
|
0.6, 2.7
|
0.3, 1.7
|
- aNo additional reason except for "other." bOne or more swollen joint count (0 to 44). cOne or more inflamed enthesis in Maastricht Ankylosing Spondylitis Enthesitis Score or fascia plantaris or both. dReference value, 0.4 mg/dl; values listed are median and quartile 1, quartile 3 because of skewed distribution. AS, ankylosing spondylitis; ETN, etanercept; IFX, infliximab; NSAIDs, nonsteroidal antiinflammatory drugs; TNF, tumor necrosis factor.
